Jeuveau vs Botox: Same 20-Unit Glabella Dose, Different US Labels

If your injector suggests Jeuveau (prabotulinumtoxinA-xvfs, nicknamed "Newtox") as an alternative to BOTOX Cosmetic (onabotulinumtoxinA), the sales pitch usually sounds straightforward: it is the same 20-unit treatment for frown lines, costs slightly less per unit, and some patients claim it kicks in faster or lasts longer.

When you look past med-spa marketing and examine the official United States Food and Drug Administration (FDA) prescribing labels, the reality is more nuanced:

1. Identical Glabellar Dosing Geometry: For glabellar frown lines ("11s"), both products are FDA-approved at the exact same pattern: 20 Units total, delivered as 4 Units (0.1 mL) into each of five discrete intramuscular injection sites (1 in the procerus, 2 in the medial corrugators, 2 in the lateral corrugators).
2. The Major Regulatory Indication Gap: BOTOX Cosmetic holds FDA approval for four distinct aesthetic indications in adults (glabellar frown lines, lateral canthal crow's feet, horizontal forehead lines, and platysma neck bands). In contrast, Jeuveau is FDA-approved for only one aesthetic indication: moderate to severe glabellar lines. Jeuveau's official Boxed Warning explicitly states it is not approved for any condition other than glabellar lines.
3. No Labeled Unit Interchangeability: Both package inserts emphasize that botulinum toxin potency units are proprietary and cannot be converted using a universal ratio. A 1:1 conversion between Botox and Jeuveau in the glabella is an injector clinical convention supported by trial dosing, not a regulatory standard.
4. Mismatched Trial Endpoints: You cannot rank Jeuveau as "68% to 70% effective" against Botox as "80% effective." Jeuveau's pivotal trials used a strict composite co-primary endpoint (requiring both the investigator and the patient to grade a ≥ 2-grade improvement), whereas Botox's trials evaluated an investigator-only rating of none or mild.
5. The "No Botox After 65" Confusion: Viral internet questions asking why neurotoxin is restricted after age 65 stem from a labeling confusion with Dysport (whose glabellar label is capped at adults under 65), not Botox or Jeuveau.

Understanding these clinical, regulatory, and pricing differences enables you to make an informed choice between the aesthetic industry's gold standard and its direct glabellar challenger.

---

Direct Answer: How Do Jeuveau and Botox Compare?

For a patient choosing between Jeuveau and BOTOX Cosmetic for facial rejuvenation:

• For frown lines (11s): Both are first-line, evidence-backed options using the identical labeled dose of 20 Units. Clinical onset, peak smoothing at Day 14, and typical duration (3 to 4 months) are clinically comparable.
• For other facial areas: If you want on-label treatment for crow's feet, forehead lines, or neck bands, BOTOX Cosmetic is FDA-approved for all three. Using Jeuveau in the forehead, crow's feet, masseters, or platysma is off-label in the United States.
• Pricing reality: Jeuveau typically retails for $10 to $15 per unit, while BOTOX Cosmetic typically retails for $12 to $20+ per unit. For a standard 20-unit glabellar treatment, Jeuveau usually costs $200 to $300, while Botox costs $240 to $400.
• Duration claims: Neither product has demonstrated superior longevity at standard labeled doses in FDA trials. Evolus's duration study showing 5- to 6-month longevity evaluated 40 Units (double the approved dose).
• Switching products: Switching is allowed, but units still do not convert by a labeled factor. True neutralizing-antibody failure is uncommon; shortened duration is more often metabolism, under-dosing, or static lines than a reason to assume Jeuveau will “reset” Botox.

---

What Is Actually FDA-Approved for Each Product?

A major point of difference between BOTOX Cosmetic and Jeuveau lies in their regulatory history and scope of approved aesthetic indications.

                     [FDA Aesthetic Indications Matrix]

   Anatomical Indication              BOTOX Cosmetic        JEUVEAU
   ────────────────────────────────   ──────────────        ───────
   Moderate to Severe Glabellar 11s   FDA-Approved (2002)   FDA-Approved (2019)
   Lateral Canthal Lines (Crow's Feet) FDA-Approved (2013)   Off-Label
   Horizontal Forehead Lines          FDA-Approved (2017)   Off-Label
   Moderate to Severe Platysma Bands  FDA-Approved (2024)*  Off-Label
   *Labeled platysma dose is 26, 31, or 36 Units, not 52 Units.

BOTOX Cosmetic (onabotulinumtoxinA)

Manufactured by Allergan Aesthetics (an AbbVie company), BOTOX Cosmetic (BLA 103000, SPL effective October 18, 2024) is the pioneer botulinum toxin type A biologic in the United States. It is FDA-approved in adults for:

1. Glabellar Lines: 20 Units total (5 injection sites of 4 U each).
2. Lateral Canthal Lines: 24 Units total (12 U per side across 3 injection sites); see our complete guide on Botox for crow's feet units and approved toxins.
3. Forehead Lines: 20 Units total (injected across 5 sites), labeled to be administered in conjunction with glabellar treatment (20 U + 20 U = 40 U total) to prevent brow ptosis.
4. Platysma Bands: 26, 31, or 36 Units depending on whether one or two vertical bands are treated per side (not 52 Units); see Botox for platysma bands and neck rejuvenation.

Jeuveau (prabotulinumtoxinA-xvfs)

Manufactured by Daewoong Pharmaceutical in South Korea and marketed in the US by Evolus, Jeuveau (BLA 761085, SPL effective April 28, 2023) was developed specifically as a dedicated aesthetic neuromodulator (often called "pure-play aesthetics").

Jeuveau received FDA approval on February 1, 2019, with a strictly bounded indication:

• Glabellar Lines Only: "Jeuveau is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated in adults for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity."

Section 1 of the Jeuveau Prescribing Information and its FDA Boxed Warning carry an explicit regulatory boundary:

"Jeuveau is not approved for the treatment of spasticity or any conditions other than glabellar lines."

While injectors commonly utilize Jeuveau off-label for forehead lines, crow's feet, masseter reduction, and lip flips, the manufacturer has not completed the clinical trial programs required to expand its US package insert to these anatomical zones. For a wider view of how all neurotoxins map across indications, see every FDA-approved neurotoxin compared. For labeled frown-line doses across all six US toxins, see Botox for 11s.

---

Are Jeuveau and Botox Units Interchangeable?

One of the most pervasive misconceptions in aesthetic medicine is that botulinum toxin units are a standardized metric like milligrams or milliliters.

                   [The Non-Interchangeability Rule]

   BOTOX Cosmetic (onabotulinumtoxinA) ──► Allergan Mouse LD50 Assay Units
   Jeuveau (prabotulinumtoxinA-xvfs)    ──► Daewoong / Evolus Proprietary Assay Units
   Dysport (abobotulinumtoxinA)         ──► Speywood Potency Units (50u glabella)
   Daxxify (daxibotulinumtoxinA-lanm)   ──► Revance Potency Units (40u glabella)

The Potency Assay Warning

Both the BOTOX Cosmetic and Jeuveau official prescribing labels state:

"The potency units of [Drug] are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of [Drug] cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method."

Each manufacturer determines unit strength using proprietary lethality assays in laboratory mice (LD50 assays). Because buffer solutions, animal strain models, reconstitution protocols, and molecular purification methods differ, "1 Unit" reflects an internal biological activity standard, not an international universal unit.

The 1:1 Glabellar Convention

In clinical practice, board-certified dermatologists and plastic surgeons dose Jeuveau at a 1:1 ratio with Botox in the glabella (20 Units of Jeuveau = 20 Units of Botox).

This convention is clinically sound because both labels use the same 20-Unit, five-site glabellar pattern. The US pivotal trials that support Jeuveau's approval (EV-001 and EV-002) were placebo-controlled, not head-to-head against Botox. A 1:1 glabellar habit is practice matching those labeled totals, not an FDA conversion factor and not proof the products are interchangeable in other areas.

---

Why You Cannot Rank Jeuveau 68% vs. Botox 80% from Trial Data

When patients research both products online, clinic blogs frequently post comparison charts showing "Jeuveau: 68% to 70% effective" alongside "Botox: 80% effective," concluding that Botox is 10% to 12% stronger.

This comparison is a classic example of flawed cross-trial analysis that ignores fundamentally different statistical endpoints.

                  [Comparing Pivotal Trial Endpoints]

   Jeuveau Pivotal Trials (EV-001 / EV-002)
   ────────────────────────────────────────
   • Enrolled: N = 654 (492 Jeuveau, 162 Placebo)
   • Co-Primary Endpoint: COMPOSITE ≥ 2-grade improvement at Day 30
   • Evaluators: BOTH Investigator (GLS) AND Subject must agree
   • Result: 68% vs 1% (EV-001), 70% vs 1% (EV-002)

   Botox Glabellar Pivotal Trials
   ──────────────────────────────
   • Enrolled: N = 537 (405 Botox, 132 Placebo)
   • Primary Endpoint: INVESTIGATOR-ONLY rating of "None or Mild" at Day 30
   • Evaluators: Investigator assessment alone
   • Result: 80% (325/405) vs 3% (4/132)

Jeuveau's Composite 2-Grade Co-Primary Endpoint

In Jeuveau's pivotal Phase 3 trials (EV-001 / NCT02334423 and EV-002 / NCT02334436), evaluating 654 subjects (492 receiving Jeuveau and 162 receiving placebo):

• Success was defined as a composite endpoint: a patient had to achieve at least a 2-grade improvement from baseline at maximum frown on Day 30 as independently rated by the investigator on the 4-point Glabellar Line Scale (GLS) AND by the subject on a 4-point scale.
• If the investigator rated a 2-grade improvement but the patient rated only a 1-grade improvement, the subject was classified as a failure.
• Under this stringent composite hurdle, the Jeuveau label reports a 68% response rate in EV-001 (vs. 1% placebo) and a 70% response rate in EV-002 (vs. 1% placebo). ClinicalTrials.gov posts the same trials as 67.5% vs 1.2% and 70.4% vs 1.3%; those are the unrounded registry figures, not a different study.

Botox's Investigator "None or Mild" Endpoint

In BOTOX Cosmetic's foundational glabellar trials (evaluated under BLA 103000):

• The primary efficacy endpoint was defined as an investigator rating of severity of none or mild at maximum frown on Day 30.
• Under this single-evaluator threshold, Botox demonstrated an 80% response rate (325/405) compared to 3% (4/132) for placebo. At Day 90, 48% remained none or mild; at Day 120, 25% remained none or mild.

Achieving a rating of "none or mild" from a single clinician is a very different mathematical hurdle than requiring simultaneous agreement between clinician and patient on a 2-step improvement from baseline. Neither label proves superior clinical performance over the other.

---

Can Jeuveau Be Used on Forehead, Crow's Feet, or Platysma?

Yes, but it is classified as off-label use.

In aesthetic medicine, off-label prescribing is entirely legal and represents standard medical practice when guided by board-certified physicians. However, understanding what off-label status means in practice helps manage expectations:

If you prioritize receiving strictly FDA-approved treatment protocols where every indication has been independently reviewed by regulatory authorities, BOTOX Cosmetic offers the broadest on-label coverage. If your primary treatment goal is frown lines, Jeuveau provides identical on-label standing.

---

Is Botox (or Jeuveau) Not Allowed After Age 65?

A frequent query in search engines is: "Why can't you get Botox after 65?"

This search trend is based on a widespread misunderstanding that conflates BOTOX Cosmetic with Dysport (abobotulinumtoxinA).

                    [The Age-65 Indication Breakdown]

   Product            Official FDA Label Indication for Glabellar Lines
   ────────────────   ──────────────────────────────────────────────────
   BOTOX Cosmetic     "Indicated in adults..." (NO upper age restriction)
   JEUVEAU            "Indicated in adults..." (NO upper age restriction)
   XEOMIN             "Indicated in adults..." (NO upper age restriction)
   DAXXIFY            "Indicated in adults..." (NO upper age restriction)
   DYSPORT            "Indicated in adults younger than 65 years of age..."
                      (Strict age boundary on FDA label BLA 125274)

Dysport's Explicit Age Ceiling

The official FDA label for Dysport (BLA 125274, Section 1.2) specifically reads:

"Dysport is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients younger than 65 years of age."

Galderma's pivotal trials for Dysport enrolled an insufficient number of patients aged 65 and older to establish statistical efficacy for that subgroup, resulting in an FDA label restricted to patients under 65. For a full comparison of these two products, see our analysis of Botox vs. Dysport and Jeuveau vs. Dysport.

Geriatric Efficacy in Botox and Jeuveau Labels

Neither BOTOX Cosmetic nor Jeuveau carries an age restriction:

• BOTOX Cosmetic: The glabellar efficacy studies included 32 subjects (6%) aged 65 and older. In the investigator table, Day-30 none-or-mild response was 39% (9/23) in that older subgroup versus 83% (316/382) in patients under 65, with a wide confidence interval on the difference.
• Jeuveau: Clinical trials included 68 subjects aged 65 and older. The label states that while response was observed, the sample size was insufficient to determine whether older patients respond differently from younger subjects.

The lower response rate in patients over 65 is physiological rather than product-specific: older skin exhibits advanced solar elastosis, structural collagen fragmentation, and deeper static creases that remain etched even when underlying muscles are fully relaxed.

---

Does Jeuveau Last Longer, and What Is the 40-Unit Trial?

Some med-spa marketing campaigns claim that Jeuveau is a "longer-lasting Newtox" that provides 5 to 6 months of line smoothing.

Standard Duration at 20 Units

At the standard FDA-approved dose of 20 Units, clinical experience and trial data show that Jeuveau lasts 3 to 4 months, which is identical to BOTOX Cosmetic:

• Onset: Initial muscle relaxation begins within 2 to 4 days.
• Peak effect: Full smoothing occurs at Day 14.
• Duration: Muscle movement begins returning around Month 3, with baseline movement recovering by Month 4; see our detailed analysis of how long Botox lasts across treatment areas.

The 40-Unit Duration Study (NCT05320393)

The marketing claim that Jeuveau lasts 5 to 6 months originates from Evolus's unlabeled 40-Unit Phase 2 program, not from the 20-Unit US label:

• NCT05320393 (completed 22 May 2023, n = 154 actual): Three arms — 40 Units of Jeuveau, 20 Units of Jeuveau, and 20 Units of BOTOX Cosmetic. There was no placebo arm.
• Posted ClinicalTrials.gov Kaplan-Meier medians for investigator return-to-baseline were 183 days for 40-Unit Jeuveau (about 26 weeks; 95% CI 153–211), versus 149 days for 20-Unit Jeuveau and 148 days for 20-Unit Botox. At the labeled 20-Unit dose, the two products were essentially the same in that analysis.

40 Units is not the FDA-approved Jeuveau glabellar dose. Doubling units also doubles cost and can increase spread risk. If on-label longer duration is the goal, that conversation belongs with Daxxify (labeled 40 Units for glabella), not with extra-strength Jeuveau; see Daxxify vs. Botox.

---

Safety Profiles, Adverse Events, and Who Should Avoid Treatment

Both BOTOX Cosmetic and Jeuveau demonstrate exceptional safety profiles when injected by trained medical professionals. Because both utilize 900 kDa botulinum toxin type A complexes, their side-effect profiles in clinical trials are very similar.

Glabellar-trial adverse reactions that can be compared from the labels:

Boxed Warning and Rare Risks

All botulinum toxin products in the US carry a class-wide FDA Boxed Warning regarding the distant spread of toxin effect. Symptoms of spread (such as dysphagia, generalized muscle weakness, or breathing difficulties) are exceptionally rare at aesthetic cosmetic doses (20 to 50 Units) and are primarily associated with large-volume therapeutic injections for spasticity (300+ Units).

Local complications in the periorbital and glabellar zone include:

• Eyelid Ptosis (Blepharoptosis): Occurred in 3% of Botox trial subjects and 2% (8 of 492) of Jeuveau subjects. Caused by toxin diffusing through the orbital septum into the levator palpebrae superioris muscle. Prevented by keeping lateral corrugator injections at least 1 cm above the supraorbital rim.
• Brow Heaviness: Occurs if frontalis muscle fibers are relaxed excessively, preventing natural brow elevation.

Contraindications

Both products are contraindicated in patients with:

• Known hypersensitivity to botulinum toxin type A or human serum albumin (both formulations contain human albumin as a stabilizer).
• Active infection at the planned injection site.
• Pre-existing motor neuropathic or neuromuscular disorders (Myasthenia Gravis, Lambert-Eaton syndrome, Amyotrophic Lateral Sclerosis).
• Pregnancy or active breastfeeding (safety not established in human clinical trials).

---

Cost Comparison: How Much Do 20 Units Cost?

Because both BOTOX Cosmetic and Jeuveau require 20 Units for a complete frown-line treatment, price comparisons are straightforward:

                  [20-Unit Glabellar Treatment Cost Math]

   Cost Factor                       JEUVEAU                   BOTOX Cosmetic
   ──────────────────────────────    ──────────────────────    ──────────────
   Average Per-Unit Price            $10 – $15 / unit          $12 – $20 / unit
   20-Unit Glabellar Session Fee     $200 – $300               $240 – $400
   Manufacturer Rewards Program      Evolus Rewards ($20–$40)  Allē Rewards ($20)
   National Physician Average*       $697                      $697
   *(ASPS 2023 Member-Surgeon Session Average across mixed multi-area treatments)

1. Unit Pricing: Jeuveau is often priced $2 to $5 less per unit than Botox in retail practices because Evolus offers competitive wholesale pricing to injectors. For an overview of market models, see how Botox is priced per unit vs. per area.
2. Rewards Programs: Evolus operates the Evolus Rewards program (frequently offering $20 to $40 credits per treatment), while Allergan operates the Allē rewards ecosystem (earning points cross-redeemable across Juvéderm, DiamondGlow, and CoolSculpting).
3. The ASPS Benchmark: The American Society of Plastic Surgeons 2023 Statistics Report lists an average physician fee for botulinum toxin procedures of $697, representing a multi-area session benchmark among board-certified surgeons.

---

Frequently Asked Questions

How many units of Jeuveau equal Botox?

For glabellar frown lines, 20 units of Jeuveau equals 20 units of Botox. Both products are FDA-labeled at 20 Units total across five injection sites. While their unit potency assays are proprietary and officially non-interchangeable, clinical practice doses them at a 1:1 ratio in the glabella.

Is Jeuveau cheaper than Botox?

Yes, in most markets. Because Evolus provides attractive wholesale pricing to practices, Jeuveau typically costs $10 to $15 per unit ($200 to $300 for frown lines), compared to $12 to $20+ per unit ($240 to $400) for BOTOX Cosmetic.

Does Jeuveau last longer than Botox?

No. At the standard FDA-approved dose of 20 Units, both Jeuveau and BOTOX Cosmetic last an average of 3 to 4 months. Marketing claims of 5- to 6-month longevity for Jeuveau stem from an experimental Phase 2 study (NCT05320393) that used 40 Units (double the labeled dose).

Can I use Jeuveau on my forehead?

Yes, but it is considered an off-label use in the United States. While Jeuveau is FDA-approved only for glabellar lines, experienced injectors frequently use it off-label to treat horizontal forehead lines (typically 8 to 15 Units, paired with glabella treatment).

Why no Botox after 65?

This is a misunderstanding. BOTOX Cosmetic has no upper age limit on its FDA label. The age-65 restriction belongs to Dysport, whose FDA label explicitly limits its glabellar indication to adults younger than 65. However, patients over 65 may experience lower response rates to any neurotoxin if their lines are deep, static creases caused by loss of skin elasticity.

Who should avoid Jeuveau?

Jeuveau should be avoided by individuals with known allergies to botulinum toxin or human albumin; active infections at the injection site; neuromuscular conditions like Myasthenia Gravis or ALS; and women who are pregnant or breastfeeding.

---

Sources

• DailyMed — JEUVEAU (prabotulinumtoxinA-xvfs) Prescribing Information (FDA-Approved Label): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a914c1-e54b-4b50-965d-b0fd9111bba4
• DailyMed — BOTOX Cosmetic (onabotulinumtoxinA) Prescribing Information (FDA-Approved Label): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485d9b71-6881-42c5-a620-a4360c7192ab
• DailyMed — DYSPORT (abobotulinumtoxinA) Prescribing Information (FDA-Approved Label): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71313a04-1349-4c26-b840-a39e4a3ddaed
• ClinicalTrials.gov — Phase 3 Study of DWP-450 in Moderate to Severe Glabellar Lines (EV-001): https://clinicaltrials.gov/study/NCT02334423
• ClinicalTrials.gov — Phase 3 Study of DWP-450 in Moderate to Severe Glabellar Lines (EV-002): https://clinicaltrials.gov/study/NCT02334436
• ClinicalTrials.gov — A Phase 2 Study to Investigate the Duration of Effect of PrabotulinumtoxinA in Glabellar Lines: https://clinicaltrials.gov/study/NCT05320393
• American Society of Plastic Surgeons — 2023 Plastic Surgery Statistics Report: https://www.plasticsurgery.org/cosmetic-procedures/botulinum-toxin
• StatPearls — Botulinum Toxin Cosmetic and Clinical Applications: https://www.ncbi.nlm.nih.gov/books/NBK557387/